|
1
|
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5.
|
Science
|
2004
|
3.95
|
|
2
|
Whither or wither microbicides?
|
Science
|
2008
|
2.17
|
|
3
|
HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
|
AIDS
|
2007
|
1.99
|
|
4
|
Evolutionary genetics: CCR5 mutation and plague protection.
|
Nature
|
2004
|
1.97
|
|
5
|
Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5.
|
Blood
|
2010
|
1.72
|
|
6
|
Fitness epistasis and constraints on adaptation in a human immunodeficiency virus type 1 protein region.
|
Genetics
|
2010
|
1.61
|
|
7
|
Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching.
|
J Virol
|
2004
|
1.50
|
|
8
|
CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro.
|
Clin Immunol
|
2003
|
1.48
|
|
9
|
Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES.
|
Antimicrob Agents Chemother
|
2003
|
1.46
|
|
10
|
Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.
|
J Virol
|
2011
|
1.12
|
|
11
|
Evolution of CCR5 use before and during coreceptor switching.
|
J Virol
|
2008
|
1.09
|
|
12
|
Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching.
|
J Virol
|
2007
|
0.93
|
|
13
|
Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.
|
PLoS One
|
2011
|
0.89
|
|
14
|
Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C.
|
J Acquir Immune Defic Syndr
|
2011
|
0.88
|
|
15
|
Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations.
|
J Virol
|
2007
|
0.86
|
|
16
|
High prevalence of infection with a single hepatitis C virus genotype in a small rural community of Argentina.
|
Liver Int
|
2006
|
0.84
|
|
17
|
CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activity.
|
J Virol
|
2012
|
0.83
|
|
18
|
"Resistance" to PSC-RANTES revisited: two mutations in human immunodeficiency virus type 1 HIV-1 SF162 or simian-human immunodeficiency virus SHIV SF162-p3 do not confer resistance.
|
J Virol
|
2010
|
0.82
|
|
19
|
Adhesion and fusion efficiencies of human immunodeficiency virus type 1 (HIV-1) surface proteins.
|
Sci Rep
|
2013
|
0.77
|
|
20
|
Changes in HIV-1 tropism: clinical and prognostic consequences.
|
Eur J Med Res
|
2007
|
0.77
|
|
21
|
Characterization of human immunodeficiency virus type 1 (HIV-1) Gag- and Gag peptide-specific CD4(+) T-cell clones from an HIV-1-seronegative donor following in vitro immunization.
|
J Virol
|
2002
|
0.76
|
|
22
|
GB virus C and mortality from HIV infection.
|
N Engl J Med
|
2002
|
0.75
|